Trial Profile
Efficacy and safety of combination therapy with GLP-1 analog lixisenatide and long-acting insulin glargine in patients with glucose intolerance or diabetes caused by hyposecretion of endogenous insulin who underwent partial pancreatectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2015
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Jun 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
- 25 Jul 2014 New trial record